AC Immune SA (ACIU) vs BioAge Labs (BIOA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AC Immune SA (ACIU) has outperformed BioAge Labs (BIOA) over the past year, losing 35.0% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $193.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | BIOA |
|---|---|---|
| Share price | $1.95 | $4.28 |
| Market cap | $193.88M | $196.67M |
| 1-day change | -8.45% | -9.13% |
| YTD return | -37.90% | -67.65% |
| 1-year return | -35.00% | -50.52% |
| 5-year return | -62.28% | — |
| Forward P/E | 2.84 | — |
| EPS (TTM) | $-0.44 | $-2.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.99M |
| Net income (latest FY) | — | $-80.61M |
| Operating margin | — | -1031.46% |
| Net margin | — | -896.11% |
| 52-week high | $3.90 | $25.96 |
| 52-week low | $1.93 | $4.24 |
| Distance from 52-week high | -50.00% | -83.51% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +331.28% | +572.43% |
| Average volume | 198.81K | 740.06K |
| Shares outstanding | 99.43M | 45.95M |
| Employees | 90 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed BIOA by 15.5 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ACIU vs BIOA FAQ
Which is bigger, AC Immune SA or BioAge Labs?
BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $193.88M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or BIOA?
ACIU returned -35.00% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and BioAge Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.